The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary clinical results of RTOG 0615.
N. Y. Lee
No relevant relationships to disclose
Q. E. Zhang
No relevant relationships to disclose
A. S. Garden
No relevant relationships to disclose
J. J. Kim
No relevant relationships to disclose
D. G. Pfister
No relevant relationships to disclose
J. Mechalakos
No relevant relationships to disclose
K. Hu
No relevant relationships to disclose
Q. Le
No relevant relationships to disclose
B. S. Glisson
No relevant relationships to disclose
A. T. C. Chan
No relevant relationships to disclose
K. K. Ang
No relevant relationships to disclose